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Abstract
Cannabinoid receptor interacting protein 1a (CRIP1a) is a CB1
receptor (CB1R) distal C-terminus-associated protein that modulates CB1R signaling via G proteins, and CB1R down-regulation
but not desensitization (Blume et al. [2015] Cell Signal., 27, 716–
726; Smith et al. [2015] Mol. Pharmacol., 87, 747–765). In this
study, we determined the involvement of CRIP1a in CB1R
plasma membrane trafﬁcking. To follow the effects of agonists
and antagonists on cell surface CB1Rs, we utilized the genetically homogeneous cloned neuronal cell line N18TG2, which
endogenously expresses both CB1R and CRIP1a, and exhibits a
well-characterized endocannabinoid signaling system. We
developed stable CRIP1a-over-expressing and CRIP1asiRNA-silenced knockdown clones to investigate gene dose
effects of CRIP1a on CB1R plasma membrane expression.
Results indicate that CP55940 or WIN55212-2 (10 nM, 5 min)
reduced cell surfaceCB1R byadynamin- andclathrin-dependent
process, and this was attenuated by CRIP1a over-expression.

CP55940-mediated cell surface CB1R loss was followed by a
cycloheximide-sensitive recovery of surface receptors (30–
120 min), suggesting the requirement for new protein synthesis.
In contrast, WIN55212-2-mediated cell surface CB1Rs recovered only in CRIP1a knockdown cells. Changes in CRIP1a
expression levels did not affect a transient rimonabant (10 nM)mediated increase in cell surface CB1Rs, which is postulated to
be as a result of rimonabant effects on ‘non-agonist-driven’
internalization. These studies demonstrate a novel role for
CRIP1a in agonist-driven CB1R cell surface regulation postulated to occur by two mechanisms: 1) attenuating internalization
that is agonist-mediated, but not that in the absence of
exogenous agonists, and 2) biased agonist-dependent trafﬁcking of de novo synthesized receptor to the cell surface.
Keywords: cannabinoid receptor interacting protein, CB1
cannabinoid receptor, CP55940, receptor trafﬁcking,
rimonabant, WIN55212-2.
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CRIP1a attenuates CB1R cell surface depletion

The cannabinoid receptor interacting protein 1a (CRIP1a) is
a CB1 cannabinoid receptor (CB1R)-associated protein, the
function of which has remained elusive (Niehaus et al.
2007). Regulation by CRIP1a of cellular signaling has been
indicated by recent studies. In the original identiﬁcation of
CRIP1a, it was shown that CB1R-mediated tonic inhibition
of N-type voltage-gated Ca2+ channels was inhibited by
CRIP1a in superior cervical ganglion neurons (Niehaus
et al. 2007). We showed that over-expression of CRIP1a in
striatal cells reduced Extracellular Signal Regulated Kinase
(ERK)1/2 phosphorylation (Blume et al. 2013). We also
showed that CB1 agonist-stimulated [35S]GTPcS binding
was attenuated by CRIP1a over-expression in HEK293 cells
stably expressing CB1R as well as in N18TG2 cells that
endogenously express both CB1R and CRIP1a, without
affecting CB1R expression levels in either cell line (Blume
et al. 2015; Smith et al. 2015). These reductions in Gprotein activation were associated with reductions in CB1R
signal transduction and downstream function in N18TG2
cells (Blume et al. 2015). Conversely, RNA interferencemediated knockdown of CRIP1a in N18TG2 cells generally
produced opposite effects on CB1R-mediated G-protein
activation and signal transduction (Blume et al. 2015;
Smith et al. 2015).
Although these studies suggest diverse roles for CRIP1a in
CB1R regulation, the underlying mechanisms involved in the
modulation of CB1R-mediated neuronal functions by
CRIP1a are just beginning to be understood. Other associated
proteins for CB1R, such as G-protein-coupled receptor
(GPCR) kinases, b-arrestins, adaptor protein 3 and GPCRassociated sorting protein 1 (GASP1), regulate CB1R
trafﬁcking and localization (Howlett et al. 2010; Smith et al.
2010). In cell model systems, exogenously expressed CB1R
can undergo rapid (5 min) sequestration or internalization
from the plasma membrane following agonist treatment
(Hsieh et al. 1999; Coutts et al. 2001; Daigle et al. 2008). In
this study, our primary focus was to determine the effects of
CRIP1a on the regulation of CB1R plasma membrane
expression and trafﬁcking during agonist and inverse agonist
occupancy of the receptor.
To investigate the role of CRIP1a on CB1R cell surface
density, we employed both CRIP1a over-expression and
RNA interference-induced CRIP1a knockdown in stably
transfected clones of the N18TG2 neuronal cell line. We
found that agonists promoted a rapid loss of cell surface
CB1R which was profoundly inhibited by the over-expression of CRIP1a. We also report an involvement of CRIP1a to
suppress the re-establishment of cell surface CB1R by de
novo synthesis following prolonged agonist exposure, and
that this effect was dependent on the agonist used. These
studies are the ﬁrst to identify a function for the CB1R
accessory protein CRIP1a in modulating changes in CB1R
cell surface localization in response to CB1R activation.
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Materials and methods
Materials
The National Institute of Drug Abuse drug supply program kindly
provided CP55940 ((-)-cis-3R-[2-hydroxy-4-(1,1-dimethylheptyl)
phenyl]-trans-4R-3(3-hydroxypropyl)-1R cyclohexanol and rimonabant (N-(piperidin-1yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-H-pyrazole-3-carboxamide). The sources for specialized
compounds were WIN55212-2 ([2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthyl)
methanone and tetrahydrolipstatin (THL, orlistat) from Cayman
Chemical (Ann Arbor, MI, USA); dynasore (3-hydroxynaphthalene2-carboxylic acid (3,4-dihydroxybenzylidene)hydrazide) from
Tocris Biosciences (Minneapolis, MN, USA); chlorpromazine,
cycloheximide and nystatin from Sigma-Aldrich (St. Louis, MO,
USA).
Cell culture models
Culture conditions, mRNA and protein quantiﬁcation of CB1R and
CRIP1a in N18TG2 neuronal wild-type (WT, untransfected) cells
and stable clones selected for CRIP1a over-expression (XS 1 and
XS 5) and siRNA-silencing knockdown (KD 2C and KD 2F) have
been described previously (Blume et al. 2015; Smith et al. 2015).
CRIP1a over-expressing N18TG2 clones have approximately a 2.3to 2.5-fold increase in both CRIP1a protein expression and the
CRIP1a : CB1R expression ratio, in comparison to untransfected
N18TG2 cells; however, in knockdown cells the molar ratio of
CRIP1a:CB1R could not be established due to low CRIP1a levels
(Smith et al. 2015). Data are shown for an empty vector pcDNA3
clone (Control), as well as two different clones of each transgenic
modiﬁcation in order to reinforce that the effects observed were as a
result of increasing or decreasing CRIP1a protein expression, rather
than an aberration as a result of transfection and cloning processes.
Immunocytochemistry determination of cell surface CB1R density
CB1R cell surface density was quantiﬁed using a 96-well format
‘On-cell-Western’ immunocytochemistry assay, as reported previously (Miller 2004; Blume et al. 2015; Smith et al. 2015). Brieﬂy,
cells at 90% conﬂuence were serum-starved (16 h), pretreated with
1 lM THL (2 h) to reduce 2-arachidonoylglycerol (2-AG) levels
and indicated enzyme inhibitors were added 15 or 30 min prior to
drug exposure. Cells were treated with vehicle, 10 nM CP55940,
10 nM WIN55212-2 or 10 nM rimonabant at 37°C for the indicated
times. The reaction was terminated by placing plates on ice, washing
with cold buffer and ﬁxing with ice-cold 1.2% phosphate-buffered
formalin (1.5 mM KH2PO4, 2.7 mM KCl, 8 mM Na2HPO4,
150 mM NaCl; 1.2% paraformaldehyde (v/v), pH 7.4) for 15 min
at 4°C. Plates were washed three times for 5 min with phosphatebuffered saline (PBS) (1.5 mM KH2PO4, 2.7 mM KCl, 8 mM
Na2HPO4, 150 mM NaCl, pH 7.4), blocked for 90 min in LI-COR
blocking buffer and incubated with gentle rocking at 4°C for 18 h
with goat anti-CB1R (N15; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) targeting the amino terminus of CB1R (1 : 800). Plates
were then washed in PBS containing 0.1% Tween-20 and incubated
simultaneously for 1 h with a secondary IR Dye 800CW donkey
anti-goat (LI-COR Biosciences, Lincoln, NE, USA) (1 : 1500) and
the nuclear stain DRAQ5 (1 : 5000) (Cell Signaling Technology,
Danvers, MA, USA) to normalize for well-to-well variations in cell
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density. Plates were washed four times with PBS Tween-20, and
immunoﬂuorescence was imaged using the LI-COR Odyssey
(169 lm resolution, 5 sensitivity, 4.01235 mm offset, medium
quality). Immunoreactive CB1R ﬂuorescence intensity was ﬁrst
normalized to DRAQ5 and then cell surface receptor values were
quantiﬁed relative to WT at time 0 min (no agonist) expressed
as 100%.
Imaging of endogenously expressed CB1R
For imaging cell surface CB1R (Fig. 2a), N18TG2 cells were plated
on coverslips coated with 0.5 mg/mL poly-D-lysine (Sigma-Aldrich)
inside wells of six-well plates. Cells that had been pretreated with
THL in serum-free Dulbecco’s modiﬁed Eagle’s medium-Ham’s
F12 (2 h) were incubated with vehicle or CP55940 (10 nM) for
15 min at 37°C. To terminate the incubation, the medium was
replaced with cold PBS, and coverslips were blocked with 4%
normal donkey serum for 30 min on ice. Surface CB1Rs were
labeled at 4°C with goat anti-CB1R antibody (N15; Santa Cruz
Biotechnology), followed by incubation with secondary donkey
anti-goat Alexa Fluor 633 (Invitrogen, Carlsbad, CA, USA).
Coverslips were mounted with ProLong Gold Anti-fade reagent
(Life Technologies, Grand Island, NY, USA) for imaging on a Zeiss
LSM 710 laser scanning confocal microscope (639 oil immersion
objective, 1.4 NA) and Zen Lite 2012TM software. All images shown
were subjected to equal parameters in Adobe Photoshop for optimal
presentation.
To quantitate internalization (Fig. 2b), cells were treated with
vehicle or CP55940 (10 nM) for 5 min at 37°C, washed with cold
PBS and blocked with 6% normal donkey serum. Surface CB1Rs
were labeled at 4°C with N15 goat anti-CB1R N-terminal antibody
followed by donkey anti-goat Alexa Fluor 633. To determine total
CB1Rs, cells were then ﬁxed with 4% paraformaldehyde in PBS
followed by permeabilization (0.1% Triton X-100 in PBS) for
10 min. Coverslips were quenched with 50 mM NH4Cl in PBS for
20 min to minimize autoﬂuorescence from paraformaldehyde.
Subsequently, total CB1Rs were labeled with a rabbit anti-CB1R
antibody targeting the C-terminus of the CB1R (Pierce Biotechnology, Rockford, IL, USA), followed by goat anti-rabbit Alexa Fluor
405 (Invitrogen). To quantitate internalization shown on confocal
images, surface CB1R immunoﬂuorescence emission intensity
(excitation at 633 nm) was divided by total CB1R immunoﬂuorescence emission intensity (excitation at 405 nm) for each individual
cell.
Statistical analyses
Statistical differences were tested using ANOVA with Bonferroni or
Dunnett’s post hoc tests. Comparisons between two groups were
performed by Student’s t-test (GraphPad Prism VI; GraphPad
Software Inc., San Diego, CA, USA).

Results
CRIP1a influences CB1R cell surface equilibrium and
translocation
We previously observed that stable CRIP1a-over-expressing
clones (XS 1 and XS 5) exhibited a cell surface CB1R level
that was 70–75% of WT (untransfected WT) N18TG2

neuroblastoma cells, a ﬁnding that might have accounted for
the reduced CB1R-mediated cellular signaling (Blume et al.
2015; Smith et al. 2015). Based on these ﬁndings, we further
developed stably expressing siRNA CRIP1a knockdown
clones (KD 2C and KD 2F) in the N18TG2 cell line, and
now use these model cell clones to test whether CRIP1a is
involved in regulating agonist-driven translocation of cell
surface CB1R. As seen in Fig. 1a and b, CP55940 mediated a
reduction in CB1R surface density that reached equilibrium
at 5 min in both WT (27  3%) and empty vector control
cells (28  4%). Similarly, WIN55212-2 produced a robust
loss of surface CB1Rs in the ﬁrst 5 min (35  5%), and
a reduced equilibrium in CB1R membrane expression at
5–10 min (31  5%) (Fig. 1c and d). CP55940-promoted
loss of CB1R surface expression in CRIP1a knockdown cells
(KD 2C and KD 2F) (Fig. 1b) was not different from WT
during the ﬁrst 5 min (KD 2C: 35  5%; KD 2F: 34  5%),
and remained constant for 30 min (KD 2C: 29  6%; KD
2F: 26  5%). CRIP1a KD cells behaved similarly to WT
during WIN55212-2 treatment at 5 min (Fig. 1d) (KD 2C:
31  5%; KD 2F: 27  6%) or 15 min (KD 2C: 28  4%;
KD 2F: 25  5%).
In contrast, in two individual clones that over-expressed
CRIP1a, treatment with CP55940 resulted in a minimal loss
in CB1R cell surface levels at 5 min (Fig. 1a) (XS 1:
12  4%; XS 5: 10  5%), which remained constant for
45 min (time course extended, data not shown) (XS 1:
13  4%; XS 5: 9  5%). Over-expression of CRIP1a also
reduced the extent of CB1R cell surface loss evoked by
WIN55212-2 at 5 min (XS 1: 14  6%; XS 5: 13  6%)
(Fig. 1c), which remained constant at 30 min (time course
extended, data not shown) (XS 1: 18  5%; XS 5:
16  6%). To corroborate the internalization dysfunction
produced by CRIP1a over-expression using a complementary
method, control and CRIP1a XS cells were visualized using
confocal microscopy (Fig. 2a). CP55940 treatment of control
cells for 15 min decreased CB1Rs that were immunolabeled
from the external surface, consistent with receptor relocation
to a compartment having limited access to extracellular
antibodies. In contrast, CRIP1a XS cells failed to exhibit a
pronounced depletion of external surface CB1R aggregates
upon agonist stimulation. Quantiﬁcation of extracellular
CB1Rs as a ratio of external surface to total CB1R ﬂuorescent
intensity (Fig. 2b) indicated that CP55940 treatment resulted
in only a 13% decrease in extracellular CB1R level in
CRIP1a XS compared with 31% in control cells.
Together, these studies indicate that cells over-expressing
CRIP1a exhibit a lower steady-state cell surface level of
CB1Rs compared with WT cells. The converse is also true:
cells that express less than endogenous CRIP1a levels exhibit
a somewhat greater steady-state cell surface level of CB1Rs
compared with WT cells. Agonist-mediated reduction in cell
surface CB1R levels could indicate that agonists mediate a
sequestration of CB1Rs away from access to N-terminal
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Fig. 1 CRIP1a affects agonist-promoted loss of cell surface CB1R.
N18TG2 wild-type (WT, untransfected), empty vector control, CRIP1a
XS (a and c) and CRIP1a KD (b and d) clones were treated with
CP55940 (10 nM) (a and b) or WIN 55212-2 (10 nM) (c and d) at
time 0. Cell surface CB1R was quantitated at indicated times as the
ratio of extracellular immunoreactive CB1R to DRAQ5. Time courses
for individual transgenic clones were calculated independently by
normalizing to time 0, and expressed as 100% for WT at time 0. Data

are presented as the mean  SEM from three independent experiments performed in triplicate. *p < 0.05, data points within the solid
line above WT and control (a, c), and WT, control and CRIP1a KD
cells (b, d) signiﬁcantly differ from time 0 for each clone. No
signiﬁcant differences from time 0 were observed at any time point for
CRIP1a XS clones. #p < 0.05, indicates signiﬁcant difference
between CRIP1a XS and WT (a, c) or CRIP1a KD and WT (b, d)
at time = 0, using Student’s t-test.

targeting antibodies such as by internalization, which can
occur at endogenously expressed CRIP1a levels (or lower).
The ﬁnding that CRIP1a over-expression attenuated this
process suggests that increasing the cellular levels of CRIP1a
can exert a negative effect on a sequestration or internalization process.

the course of a 10-min treatment with CP55940 was only
8  5% for WT cells and 7  6% for control cells. These
experiments indicate that the majority of CB1Rs that were
depleted from the plasma membrane in response to agonist
treatment required dynamin. Dynasore treatment did not
antagonize or augment the attenuation by CRIP1a of
CP55940- or WIN55212-2-evoked loss of cell surface
CB1R over the 10 min time course, or beyond to 120 min
(data not shown). The lack of additivity of CRIP1a overexpression with dynasore treatment implicates a dynaminmediated CB1R process being suppressed by both. Dynasore treatment did not affect the steady-state level of cell
surface CB1R in WT, control, CRIP1a XS or CRIP1a KD
cells (a–f; 0 min, no agonist).
To ascertain which internalization or sequestration mechanism(s) play a role in the effects of CRIP1a over-expression
on CP55940-promoted cell surface CB1R depletion, we used
chlorpromazine and nystatin to disrupt internalization mediated by clathrin and caveolae, respectively. In Fig. 4(a),
pretreatment of WT and control cells with chlorpromazine,
an effective inhibitor of clathrin-mediated internalization
(Wang et al. 1993; Rejman et al. 2005), revealed that cell
surface levels of CB1R were only marginally reduced by
CP55940 (WT, 5 min, 12  4.2%) compared with untreated

CRIP1a affects agonist-mediated cell surface CB1R depletion
through dynamin and clathrin-dependent mechanisms
Internalization of surface receptors occurs mainly through
two well-characterized structures, clathrin-coated invaginations and caveolae from lipid rafts (Drake et al. 2006). The
GTPase dynamin functions in both clathrin- and caveolaemediated endocytosis (Gold et al. 1999; Mayor and Pagano
2007). To elucidate the internalization mechanism that
CRIP1a over-expression suppresses, we blocked dynamin
with the inhibitor dynasore and examined net cell surface
CB1Rs. Figure 3 shows that during dynamin blockade,
there were no signiﬁcant decreases in the cell surface levels
of CB1R after CP55940 (a–c)- or WIN55212-2 (d–f)treatment over the 10 min time course versus time 0 (no
agonist) for WT or control (a and d), CRIP1a XS (b and e)
or CRIP1a KD (c and f) clones. After treatment with
dynasore, the average reduction in cell surface CB1R over
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Control

(5 min, WT: 37  5%; Control: 40  6%), typical of that
observed in the absence of nystatin (Fig. 4d). Similarly,
pretreatment with nystatin did not alter the CP55940mediated cell surface CB1R depletion in CRIP1a KD cells
(5 min, CRIP1a KD 2C: 40  7%) (Fig. 4f). Nystatin
treatment also failed to affect the attenuated CP55940mediated CB1R cell surface loss in CRIP1a over-expressing
cells (Fig. 4e: 5 min, CRIP1a XS 1, 13  4%). The failure
of nystatin to alter the rate or extent of agonist-mediated cell
surface changes in CB1R does not support the involvement
of a caveolar mechanism.

CRIP1a XS1

CP55940

Basal

(a)

External versus total CB1R
Relative fluorescence ratio

(b)

1.5

10 µm
Veh
CP55940

1.0

**
0.5

0.0
Control

CRIP1a XS1

Fig. 2 CRIP1a over-expression attenuates agonist-promoted CB1R
cell surface depletion. N18TG2 empty vector control, and CRIP1a XS
cells were treated with vehicle (Veh) or CP55940 (10 nM) for 15 min
(a). Surface CB1Rs were ﬂuorescently labeled (red) as described in
Materials and methods. The scale bar for images is 10 lm. (b) Control
or CRIP1a XS cells were treated with vehicle or CP55940 (10 nM) for
5 min, and external CB1Rs were labeled with a goat N-terminal CB1R
antibody, followed by ﬁxation, permeabilization and labeling of total
CB1Rs with a rabbit C-terminal CB1R antibody. Quantiﬁcation is
reported as the mean ratio of external/total ﬂuorescence of cells
examined across four ﬁelds from 1 or 2 coverslips each in three
independent experiments, for a total of 48–60 cells per condition.
**p < 0.01 signiﬁcantly different CP55940 versus vehicle ANOVA with
Bonferroni post hoc test.

cells. Chlorpromazine also attenuated CP55940-mediated
cell surface CB1R loss in CRIP1a KD cells (Fig. 4c)
(1–5 min, CRIP1a KD 2C, 14  6.1%). Chlorpromazine
neither antagonized nor augmented the attenuation of
CP55940-mediated cell surface CB1R depletion in CRIP1a
XS cells (Fig. 4b: 1–5 min, CRIP1a XS 1, 11  5.2%). The
lack of additivity implicates a chlorpromazine-sensitive
process and the mechanism affected by over-expression of
CRIP1a as being contiguous or related processes.
Experiments have also demonstrated a role for lipid rafts in
trafﬁcking of anandamide-activated CB1Rs to the lysosomal
sorting pathway in human breast cancer MDA-MB-231 cells
(Sarnataro et al. 2005) or in non-agonist-driven recycling of
CB1Rs in C6 glioma cells (Bari et al. 2005). We tested the
role of CRIP1a in lipid raft sequestration and caveolar
internalization. WT and control cells were preincubated with
nystatin to sequester cholesterol and disrupt lipid rafts
(Cuitino et al. 2005), and then treated with CP55940. These
cells displayed a prominent loss in cell surface CB1Rs

CRIP1a involvement in CB1R cell surface translocation
during prolonged ligand occupancy
After prolonged CP55940 exposure, a gradual and complete
recovery of CB1R surface expression occurred in WT cells
(Fig. 5a and b). In WT or control cells, a return to pre-agonist
steady-state levels (100%) was observed between 15 min
and 120 min of CP55940 exposure. However, CRIP1a XS
cells remained at 70% of WT levels during this prolonged
CP55940 exposure. During the re-establishment of CB1R
cell surface density, CRIP1a KD cells showed a modest
enhancement in CB1R surface density relative to WT,
returning to the same equilibrium levels above WT
(120 min, WT: 96  3%; KD 2C: 109  4%; KD 2F:
116  7%). These studies suggest that a recovery of CB1R
to the cell surface during prolonged CP55940 occupancy
occurs by a mechanism that reaches the same CB1R density
as the pre-agonist levels. Furthermore, the steady-state CB1R
level achieved during recovery is related to the amount of
CRIP1a expressed (i.e., higher than endogenous CRIP1a:
lower CB1R; lower than endogenous CRIP1a: higher CB1R).
Unlike cells treated with CP55940, WT or control cells
exposed to WIN55212-2 failed to re-establish pre-agonist
surface levels of CB1R during a 30-min to 120-min treatment
period (Fig. 5c and d). After prolonged treatment with
WIN55212-2, CB1R surface expression remained at
25  6% below the initial level in WT cells. In CRIP1a
XS cells, CB1R membrane expression remained signiﬁcantly
below the pre-WIN55212-2 WT densities (120 min, WT:
75  5%; XS 1: 50  6%; XS 5: 56  5%). However, in
CRIP1a KD cells, CB1R cell surface density fully returned to
pre-WIN55212-2 values (KD 2C: 109  5%; KD 2F:
116  5%) (Fig. 5d). Final steady-state CB1R surface levels
were signiﬁcantly different between WT cells (120 min, WT:
78  5%) and CRIP1a KD cells (120 min, KD 2C:
109  6%; KD 2F: 112  5%). These data suggest that
there is an agonist-biased mechanism of establishing cell
surface density of CB1R, such that CRIP1a at endogenous
levels or greater can suppress the level of cell surface
receptors under the inﬂuence of WIN55212-2.
In order to characterize the mechanism(s) involved in reestablishing the cell surface density of CB1R during
prolonged agonist treatment, we examined whether new
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Fig. 3 CRIP1a modulates agonist-promoted, dynamin-dependent
CB1R cell surface depletion. N18TG2 wild-type (WT) and empty
vector control cells (a, d), CRIP1a XS (b, e) and CRIP1a KD clones
(c, f) were pretreated for 30 min with vehicle or the dynamin inhibitor
dynasore (80 lM), and challenged with the CB1R agonists CP55940
(10 nM) (a–c) or WIN55212-2 (10 nM) (d–f) for the indicated times.
CB1R cell surface density was quantitated using the On-cell-Western
assay, and CB1R surface expression was determined as the ratio of
immunoreactive CB1R to DRAQ5, represented as 100% at time 0 for
WT. Time course data were compared independently to time 0 for each

transgenic clone. In (a, c, d, f) *p < 0.05, the solid line below untreated
WT, control and CRIP1a KD cells indicates that inclusive data points
signiﬁcantly differ from time 0 for WT, Control and CRIP1aKD cells
using Student’s t-test. (b and e) No signiﬁcant differences from time 0
were detected in CRIP1aXS clones in the presence or absence of
dynasore. (a–f) No signiﬁcant differences from time 0 were detected for
dynasore-treated cells for any of the clones. Data are presented as the
mean  SEM from four independent experiments performed in duplicate.

protein synthesis was required. The re-establishment of
CB1R surface density following prolonged CP55940 treatment (60–120 min) was signiﬁcantly blocked in the presence
of the protein synthesis inhibitor cycloheximide in WT and
empty vector control cells (Fig. 6a) and CRIP1a KD (Fig. 6c).
In CP55940-treated CRIP1a XS cells, a signiﬁcant loss in
CB1R density at the cell surface was observed from 60 to
120 min treatment with cycloheximide (Fig. 6b). This demonstrates that de novo protein synthesis is required to maintain
levels of CB1R at the plasma membrane, independent of the
degree of agonist-dependent CB1R cell surface depletion.
In WIN55212-2-treated WT or control cells (Fig. 6d) or
CRIP1a XS cells (Fig. 6e), cycloheximide reduced CB1R

surface density marginally (not signiﬁcantly different from
the absence of cycloheximide). However, cycloheximide
abolished CB1R cell surface re-population during 60 to
120 min WIN55212-2 exposure in CRIP1a KD cells
(Fig. 6f), demonstrating that in the reduced CRIP1a environment, the recovery of cell surface CB1R required new
protein synthesis. In the described protocol, cycloheximide
added 30 min prior to agonist challenge did not alter basal
(pre-agonist) CB1R cell surface levels in WT, control or the
CRIP1a transgenic clones (Fig. 6a–f), or total CB1R or
CRIP1a protein expression (data not shown). Of note, the
presence of cycloheximide had no signiﬁcant effect on the
processes of agonist-mediated cell surface depletion
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Fig. 4 CRIP1a modulates agonist-promoted CB1R loss through a
clathrin-mediated but not caveolin-mediated mechanism. Cells were
pretreated for 30 min with vehicle (DMSO), 25 lM chlorpromazine
(CPZ, a–c) or 25 lM nystatin (NYS, d–f), and challenged for the
indicated times with CP55940 (10 nM). On-cell-Western analysis of
CB1R cell surface expression was quantitated as described in
Materials and methods. Time courses for individual transgenic
clones were calculated independently by normalizing to time 0,
and expressed as 100% for wild type (WT) at time 0. Data are
presented as the mean  SEM calculated from three independent

experiments performed in triplicate. #Indicates a signiﬁcant difference p < 0.05 at time point 0 between CRIP1a XS and WT (b, e)
and between WT and CRIP1a KD (c, f) clones. *Indicates time
points within the solid line for WT and control (a), control (b) and
control or CRIP1a KD (c) at which CPZ-treated were signiﬁcantly
different from non-treated values (p < 0.05) using Student’s t-test.
No signiﬁcant differences were observed between CPZ-treated and
non-treated values in CRIP1a XS cells (b). No signiﬁcant differences
were observed between NYS-treated and non-treated values in any
cell clones (d–f).

(1–5 min) or the prolonged period of reduced steady-state
levels (5–30 min) before recovery (Fig. 6a–f).
The CB1 antagonist/inverse agonist rimonabant has been
reported to promote and stabilize CB1R cell surface expression postulated in those studies to be because of blocking
non-agonist-driven ‘constitutive’ internalization of CB1Rs
(Rinaldi-Carmona et al. 1998; Leterrier et al. 2004; McDonald et al. 2007). In our studies, treatment of WT and control
cells with rimonabant (10 nM) in the absence of agonists
caused an increase in CB1R surface expression over basal
(5 min, WT: 114  5%), which reached its peak at 15 min
(133  6%), before re-establishing the baseline levels at
60 min (106  6%) (Fig. 7a and b). As shown in Fig. 7(a),
an increase in CB1R surface expression resulted following

rimonabant treatment for CRIP1a XS (5 min, XS 1:
112  5%; XS 5: 113  6%), with maximal CB1R surface
expression occurring at 15 min (XS 1: 134  5%; XS 5:
127  8%). CRIP1a KD cells (Fig. 7b) also exhibited an
observable increase at 5 min (KD 2C: 126  4%; KD 2F:
128  5%) and maximal surface expression at 15 min (KD
2C: 142  5%; KD 2F: 141  6%). For all cells that
expressed CRIP1a at all levels, the CB1R surface expression
was re-established to steady-state WT levels after 120 min
treatment with rimonabant. This means that the CRIP1a XS
clones displayed an augmentation (~ 26%) in CB1R surface
expression after 120-min exposure to rimonabant compared
with the initial levels in these clones (Fig. 7a), suggesting
that the suppression of steady-state levels of CB1R by
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Fig. 5 CRIP1a modulates CB1R surface recovery during agonist
challenge in an agonist-dependent manner. An extended time course
is shown for CP55940- (a and b) or WIN55212-2 (c and d) mediated
CB1R cell surface levels in N18TG2 wild-type (WT), empty vector
control, CRIP1a XS (a and c) and CRIP1a KD (b and d) clones. Cells
were serum-starved for 16 h, pretreated with 1 lM tetrahydrolipstatin
for 2 h, and treated with 10 nM of the CB1R agonist CP55940 or
WIN55212-2 for the indicated times. CB1R cell surface expression
was quantitated using the On-cell-Western assay, and determined as

the ratio of immune-reactive CB1R to DRAQ5 ﬂuorescence. Time
courses for individual transgenic clones were calculated independently by normalizing to time 0, and expressed as 100% for WT at
time 0. Data are presented as the mean  SEM from three
independent experiments performed in triplicate. #p < 0.05, the solid
line indicates signiﬁcant difference between CRIP1a XS and WT (a,
c) or CRIP1a KD and WT (b, d) at the same time point, using
Student’s t-test.

CRIP1a over-expression can be relieved in the presence of
rimonabant.

sequestration or internalization occurring from clathrincoated pits. Our studies focused on the ability of the small
associated protein CRIP1a to modulate these processes.
Our data support the premise that over-expression of
CRIP1a can suppress the agonist-driven CB1R sequestration
or internalization processes. This ﬁnding can have relevant
implications for cells that express CRIP1a, because in
GPCRs that undergo internalization and trafﬁcking to distinct
intracellular compartments, deﬁcits in GPCR internalization
can affect signaling pathway selectivity (Drake et al. 2006;
Hanyaloglu and von Zastrow 2008). In many cell types,
GPCRs are directed into the recycling pathway for resensitization and return to the plasma membrane, or to
lysosomes for termination of receptor signaling via degradation (Drake et al. 2006; Hanyaloglu and von Zastrow 2008).
Mechanisms responsible for agonist-dependent CB1R
internalization have been reported to involve a sequence of
events including the activation of GPCR kinases, and the
subsequent recruitment of b-arrestin2 (Hsieh et al. 1999;
Daigle et al. 2008; Stadel et al. 2011; Nguyen et al. 2012).
CB1Rs have been shown to rapidly internalize following
a short (5 min) exposure to a CB1R agonist in AtT20
cells (Hsieh et al. 1999; Jin et al. 1999), HEK293 cells

Discussion
Data presented here show that in the N18TG2 neuronal cell
line, which endogenously expresses both CB1R and CRIP1a
at their native stoichiometry, agonist occupancy can reduce a
pool of cell surface CB1Rs within minutes. This pool is
limited to only a fraction (30–40%) of surface CB1Rs, and
reaches a new equilibrium at the cell surface (from 5 min to
30 min) that remains below the pre-agonist cell surface
levels until de novo synthesized receptors appear on the
plasma membrane. Previous studies indicated that both CB1R
and CRIP1a appeared predominantly in Na/K-ATPasecontaining membranes from the N18TG2 cells, with a
smaller fraction of both proteins in an NP40-insoluble,
caveolin 1-containing fraction (Blume et al. 2015). The data
herein demonstrate that agonist-stimulated CB1R cell surface
depletion occurs via a dynamin-dependent process in a
nystatin-resistant mechanism. The majority of cell surface
loss occurred via a chlorpromazine-sensitive mechanism,
consistent with the majority of agonist-dependent
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(Leterrier et al. 2004) and hippocampal neurons (Coutts
et al. 2001; Leterrier et al. 2006). Elegant studies using live
cell total internal reﬂection ﬂuorescence microscopy have
indicated that agonists can selectively retain CB1R-b-arrestin
complexes in clathrin-coated pits at the cell surface prior to
internalization (Flores-Otero et al. 2014; Delgado-Peraza
et al. 2016). CB1R internalization requires dynamin as
evidenced by the impairment of receptor endocytosis in
cultured hippocampal neurons expressing dominant-negative
dynamin isoforms (Leterrier et al. 2006). Hsieh et al. (1999)
were the ﬁrst to report clathrin-mediated endocytosis as the
main route for agonist-promoted removal of cell surface
CB1Rs. More recent studies demonstrated that agonistpromoted CB1R internalization can occur via both clathrin
and caveolin pathways, which together were reported to
account for endocytosis of ~ 40% of receptors (Keren and
Sarne 2003; Wu et al. 2008). Our assays are based on an
antibody interaction with the CB1R N-terminus, which
would not be accessible after a coated pit has closed in a
dynamin-dependent mechanism. In addition to CRIP1a’s
function to suppress agonist-mediated internalization of
CB1Rs, a recent disclosure indicated that the Src homology
3-domain growth factor receptor-bound 2-like (endophilin)interacting protein 1 can also interact with the CB1R to

Fig. 6 De novo CB1R synthesis is required
for re-establishing surface membrane
receptor density during prolonged agonist
exposure. N18TG2 wild-type (WT), empty
vector control (a and d), CRIP1a XS (b and
e) and CRIP1a KD (c and f) clones were
pretreated for 30 min with vehicle or the
protein synthesis inhibitor cycloheximide
(HEX) (1 lM), and then challenged for the
indicated times with the CP55940 (10 nM)
(a–c) or WIN55212-2 (10 nM) (d–f). CB1R
cell surface levels were quantitated by Oncell Western assays, and determined as %
of CB1R at time 0, and expressed as 100%
for each clone individually at time 0. Data
are calculated from three independent
experiments performed in triplicate, and
represented
as
the
mean  SEM.
*p < 0.05 indicates time points at which
HEX values were signiﬁcantly different from
non-treated using Student’s t-test.

inhibit agonist-driven, clathrin-mediated endocytosis of the
CB1R (Hajkova et al. 2016).
We previously reported that exogenous CRIP1a overexpression could attenuate CB1R down-regulation but not
desensitization (Smith et al. 2015). Prolonged treatment with
cannabinoid agonists leads to CB1R down-regulation in
rodent brains, as evidenced by decreases in CB1R
immunoblotting and [3H]rimonabant Bmax values (SimSelley et al. 2006). Delta9-Tetrahydrocannabinol-induced
down-regulation of CB1Rs was attenuated in the cerebellum
and spinal cord of b-arrestin2 knockout mice relative to WT
littermates (Nguyen et al. 2012). Martini et al. (2007)
reported evidence that binding of GASP1 to the CB1R
resulted in CB1R trafﬁcking to lysosomes and receptor
degradation during prolonged treatment with WIN55212-2.
Our ﬁnding that the re-establishment of cell surface CB1R
levels during extended periods of agonist exposure requires
de novo synthesis is consistent with the degradation, rather
than recycling, of internalized receptors, and is consistent
with the degradation of internalized receptors reported from
studies of AtT20 cells and the striatum of ICR mice (Hsieh
et al. 1999; Sim-Selley et al. 2006).
In agreement with previous work performed in HEK293
and primary cultured neurons (Martini et al. 2007), we
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Fig. 7 CRIP1a levels do not inﬂuence inverse agonist-promoted
increase in cell surface CB1R density. The time course for rimonabant-mediated changes in CB1R cell surface expression compares
N18TG2 wild-type (WT) and empty vector Control to CRIP1 XS clones
(a), and CRIP1a KD clones (b). Cells were pretreated with 1 lM
tetrahydrolipstatin for 2 h, and then challenged with the CB1R
antagonist rimonabant (10 nM) for the indicated times. Quantiﬁcation
of CB1R cell surface expression was determined using the On-cellWestern assay. Each time point was normalized to time 0 for each
clone, but expressed as 100% for WT at time 0. The mean  SEM
were calculated from four independent experiments performed in
triplicate. No signiﬁcant differences were observed between WT,
CRIP1a XS, and CRIP1a KD clones at any time point, except time 0
(p < 0.05, Student’s t-test).

discovered that there were agonist-speciﬁc differences in the
return of cell surface CB1Rs to steady-state levels: CB1R
surface expression returned to pre-agonist levels following
prolonged treatment with CP55940, but not WIN55212-2.
The failure of WIN55212-2-occupied CB1R to re-establish
pre-agonist steady-state plasma membrane levels could be
overcome if CRIP1a expression was reduced below endogenous levels (Fig. 5d). This suggests that CRIP1a at endogenous levels serves a function to suppress plasma membrane
CB1R. One mechanism is that CRIP1a could increase the rate
of degradation of plasma membrane CB1Rs. This possibility
is unlikely, because: (i) CRIP1a over-expression suppresses
internalization (Fig. 1) which is required as a ﬁrst step
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leading to degradation; and (ii) CRIP1a over-expression in
the HEK293 cell model reduced CB1R down-regulation
(Smith et al. 2015). Martini et al. (2007) determined that
agonist-promoted down-regulation of CB1R over a similar
time course in HEK293 cells was mediated by the association
of CB1R with GASP1, resulting in targeting the receptor to
the lysosomal degradation pathway.
A more likely mechanism for the suppression of cell
surface CB1R levels by CRIP1a over-expression, as well as
the ability of CRIP1a knockdown to rescue CB1R steadystate levels following prolonged WIN55212-2 treatment, is
that CRIP1a could suppress the trafﬁcking of nascent CB1R
to the plasma membrane. Early studies identiﬁed a pool of
CB1Rs in N18TG2 neuronal cells that are localized in the
perinuclear compartment (McIntosh et al. 1998), potentially
providing a source of receptors that could be translocated to
the plasma membrane. The re-appearance of CB1Rs on the
cell surface after prolonged agonist exposure may be because
of translocation of newly synthesized receptors sequestered
this pool.
The ability of rimonabant to increase CB1R cell surface
expression has been attributed to its inverse agonist effects
to block ‘constitutive’ internalization of CB1Rs (RinaldiCarmona et al. 1998; Leterrier et al. 2004; McDonald et al.
2007). We did not observe any signiﬁcant inﬂuence of
CRIP1a levels on the rate or extent of the transient increase
in CB1R density at the cell surface by rimonabant (Fig. 7).
The experiments reported herein were conducted by
removal of serum to eliminate variability in exposure to
that source of endocannabinoids, as well as THL to inhibit
diacylglycerol lipase and reduce 2-arachidonoylglycerol (2AG) levels (Smith et al. 2015). These precautions reduce
‘endocannabinoid tone’ that could activate the CB1R.
Gyombolai et al. (2013) found that clathrin was required
for both exogenous agonist- and non-agonist-stimulated
internalization of CB1R in Neuro2A and HeLa cells,
whereas b-arrestin2 was required only for agonist-driven
but not the ‘constitutive’ internalization of CB1R. Thus,
there may be differences between the agonist-stimulated
versus non-agonist-mediated internalization that allows
CRIP1a to regulate agonist-driven events alone. The data
showing that rimonabant could overcome CRIP1a-mediated
suppression of CB1R cell surface steady state (Fig. 7a)
suggest that binding of rimonabant to the CB1R can
preclude or reverse the inﬂuence of CRIP1a. Although there
may be complex interpretations of ‘constitutive’ activity
versus ‘constitutive’ internalization in the absence of
exogenous agonists, or ‘endocannabinoid tone’ resulting
in autocrine or paracrine responses, our studies of transgenic cells altered in CRIP1a expression demonstrate a
CRIP1a regulation of steady-state cell surface CB1R in the
N18TG2 neuronal model. Our ﬁndings provide a rationale
to investigate the inﬂuence of CRIP1a on CB1R in more
complex in vivo animal models.
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Overall, these ﬁndings identify a novel function for
CRIP1a in regulating agonist-promoted CB1R internalization. We propose that CRIP1a serves to ﬁne-tune the extent
of CB1R internalization and cell surface expression. Our data
suggest that CRIP1a also functions in the delivery of newly
synthesized CB1Rs. Drug development using CB1R agonists
and antagonists has had limited success because of untoward
side effects. The ability of CRIP1a to modulate CB1R cell
surface levels in those cell types that express CRIP1a
suggests that changes in CRIP1a expression could provide a
mechanism to modulate CB1R abundance on the cell surface,
and offers a potentially promising approach to the development of more selective CB1R pharmacotherapies. Future
studies will determine whether CRIP1a has any interactions
with GASP1 or Src homology 3-domain growth factor
receptor-bound 2-like (endophilin)-interacting protein 1, or
how CRIP1a may be involved with the AP-2 complex and
associated adaptor proteins such as b-arrestin, ARF and Rho
G proteins, epsin, amphiphysins and Eps15 (Kelly and Owen
2011; Croise et al. 2014; Paczkowski et al. 2015). Further
investigation is necessary to address issues of differences in
CB1R expression levels particularly between endogenously
expressed versus stably transfected receptors in host cell
models, biased ligand inﬂuences, treatment time courses and
other cell regulatory inﬂuences.
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